784 related articles for article (PubMed ID: 20397318)
1. Signaling pathways perturbing muscle mass.
Glass DJ
Curr Opin Clin Nutr Metab Care; 2010 May; 13(3):225-9. PubMed ID: 20397318
[TBL] [Abstract][Full Text] [Related]
2. PI3 kinase regulation of skeletal muscle hypertrophy and atrophy.
Glass DJ
Curr Top Microbiol Immunol; 2010; 346():267-78. PubMed ID: 20593312
[TBL] [Abstract][Full Text] [Related]
3. The IGF-1/PI3K/Akt pathway prevents expression of muscle atrophy-induced ubiquitin ligases by inhibiting FOXO transcription factors.
Stitt TN; Drujan D; Clarke BA; Panaro F; Timofeyva Y; Kline WO; Gonzalez M; Yancopoulos GD; Glass DJ
Mol Cell; 2004 May; 14(3):395-403. PubMed ID: 15125842
[TBL] [Abstract][Full Text] [Related]
4. SIRT1 protein, by blocking the activities of transcription factors FoxO1 and FoxO3, inhibits muscle atrophy and promotes muscle growth.
Lee D; Goldberg AL
J Biol Chem; 2013 Oct; 288(42):30515-30526. PubMed ID: 24003218
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of FoxO transcriptional activity prevents muscle fiber atrophy during cachexia and induces hypertrophy.
Reed SA; Sandesara PB; Senf SM; Judge AR
FASEB J; 2012 Mar; 26(3):987-1000. PubMed ID: 22102632
[TBL] [Abstract][Full Text] [Related]
6. C/EBPβ mediates tumour-induced ubiquitin ligase atrogin1/MAFbx upregulation and muscle wasting.
Zhang G; Jin B; Li YP
EMBO J; 2011 Aug; 30(20):4323-35. PubMed ID: 21847090
[TBL] [Abstract][Full Text] [Related]
7. Cryptotanshinone prevents muscle wasting in CT26-induced cancer cachexia through inhibiting STAT3 signaling pathway.
Chen L; Yang Q; Zhang H; Wan L; Xin B; Cao Y; Zhang J; Guo C
J Ethnopharmacol; 2020 Oct; 260():113066. PubMed ID: 32505837
[TBL] [Abstract][Full Text] [Related]
8. Photobiomodulation therapy moderates cancer cachexia-associated muscle wasting through activating PI3K/AKT/FoxO3a pathway.
Li Y; Chen Y; Liao Y; Huang T; Tang Q; He C; Xu L; Chang H; Li H; Liu Q; Lai D; Xia Q; Zou Z
Apoptosis; 2024 Jun; 29(5-6):663-680. PubMed ID: 38598070
[TBL] [Abstract][Full Text] [Related]
9. Molecular signaling pathways regulating muscle proteolysis during atrophy.
Franch HA; Price SR
Curr Opin Clin Nutr Metab Care; 2005 May; 8(3):271-5. PubMed ID: 15809529
[TBL] [Abstract][Full Text] [Related]
10. Atrogin-1, MuRF1, and FoXO, as well as phosphorylated GSK-3beta and 4E-BP1 are reduced in skeletal muscle of chronic spinal cord-injured patients.
Léger B; Senese R; Al-Khodairy AW; Dériaz O; Gobelet C; Giacobino JP; Russell AP
Muscle Nerve; 2009 Jul; 40(1):69-78. PubMed ID: 19533653
[TBL] [Abstract][Full Text] [Related]
11. Myostatin reduces Akt/TORC1/p70S6K signaling, inhibiting myoblast differentiation and myotube size.
Trendelenburg AU; Meyer A; Rohner D; Boyle J; Hatakeyama S; Glass DJ
Am J Physiol Cell Physiol; 2009 Jun; 296(6):C1258-70. PubMed ID: 19357233
[TBL] [Abstract][Full Text] [Related]
12. Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy.
Sandri M; Sandri C; Gilbert A; Skurk C; Calabria E; Picard A; Walsh K; Schiaffino S; Lecker SH; Goldberg AL
Cell; 2004 Apr; 117(3):399-412. PubMed ID: 15109499
[TBL] [Abstract][Full Text] [Related]
13. Transgenic overexpression of locally acting insulin-like growth factor-1 inhibits ubiquitin-mediated muscle atrophy in chronic left-ventricular dysfunction.
Schulze PC; Fang J; Kassik KA; Gannon J; Cupesi M; MacGillivray C; Lee RT; Rosenthal N
Circ Res; 2005 Sep; 97(5):418-26. PubMed ID: 16051886
[TBL] [Abstract][Full Text] [Related]
14. Muscle-specific E3 ubiquitin ligases are involved in muscle atrophy of cancer cachexia: an in vitro and in vivo study.
Yuan L; Han J; Meng Q; Xi Q; Zhuang Q; Jiang Y; Han Y; Zhang B; Fang J; Wu G
Oncol Rep; 2015 May; 33(5):2261-8. PubMed ID: 25760630
[TBL] [Abstract][Full Text] [Related]
15. Myostatin induces degradation of sarcomeric proteins through a Smad3 signaling mechanism during skeletal muscle wasting.
Lokireddy S; McFarlane C; Ge X; Zhang H; Sze SK; Sharma M; Kambadur R
Mol Endocrinol; 2011 Nov; 25(11):1936-49. PubMed ID: 21964591
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of Stat3 activation suppresses caspase-3 and the ubiquitin-proteasome system, leading to preservation of muscle mass in cancer cachexia.
Silva KA; Dong J; Dong Y; Dong Y; Schor N; Tweardy DJ; Zhang L; Mitch WE
J Biol Chem; 2015 Apr; 290(17):11177-87. PubMed ID: 25787076
[TBL] [Abstract][Full Text] [Related]
17. Skeletal muscle hypertrophy and atrophy signaling pathways.
Glass DJ
Int J Biochem Cell Biol; 2005 Oct; 37(10):1974-84. PubMed ID: 16087388
[TBL] [Abstract][Full Text] [Related]
18. Myostatin induces cachexia by activating the ubiquitin proteolytic system through an NF-kappaB-independent, FoxO1-dependent mechanism.
McFarlane C; Plummer E; Thomas M; Hennebry A; Ashby M; Ling N; Smith H; Sharma M; Kambadur R
J Cell Physiol; 2006 Nov; 209(2):501-14. PubMed ID: 16883577
[TBL] [Abstract][Full Text] [Related]
19. Molecular mechanisms modulating muscle mass.
Glass DJ
Trends Mol Med; 2003 Aug; 9(8):344-50. PubMed ID: 12928036
[TBL] [Abstract][Full Text] [Related]
20. The role of TGF-β signaling in muscle atrophy, sarcopenia and cancer cachexia.
Lan XQ; Deng CJ; Wang QQ; Zhao LM; Jiao BW; Xiang Y
Gen Comp Endocrinol; 2024 Jul; 353():114513. PubMed ID: 38604437
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
